Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04205812
Title Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (POD1UM-304)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Incyte Corporation
Indications

lung non-small cell carcinoma

Therapies

Retifanlimab

Pemetrexed Disodium

Carboplatin + Nab-paclitaxel

Cisplatin + Pemetrexed Disodium

Carboplatin + Pemetrexed Disodium + Retifanlimab

Carboplatin + Nab-paclitaxel + Retifanlimab

Cisplatin + Pemetrexed Disodium + Retifanlimab

Pemetrexed Disodium + Retifanlimab

Carboplatin + Pemetrexed Disodium

Carboplatin + Paclitaxel + Retifanlimab

Carboplatin + Paclitaxel

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.